Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
PROTECTION AGAINST ischemia-reperfusion injury may have a potential benefit in three distinct clinical situations: 1) limiting reperfusion injury in patients presenting with ST-elevation acute myocardial infarction before undergoing reperfusion therapy; 2) short-to intermediate-term treatment before elective procedures that may pose a risk for myocardial ischemia, such as cardiac or noncardiac surgery or percutaneous coronary interventions; and 3) long-term treatment in patients with established coronary artery disease to minimize the damage from an effort-induced ischemia or a potential future myocardial infarction. In the present study we studied whether the myocardial protection effects of intermediate-term pretreatment with pioglitazone (Pio) is dependent on nitric oxide (NO) synthases (NOSs), using a model that may be relevant to the second option mentioned above.
Periprocedural myocardial infarction following surgery or percutaneous coronary interventions are associated with mortality and morbidity (39) . Of the 11 million adults aged over 50 yr undergoing noncardiac surgery in the United States annually (www.CDC.gov), 3.9% will suffer a major perioperative cardiac event and 1.3% (or 143,000 patients) will have a fatal cardiac event (39) . The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to decrease cardiovascular morbidity and mortality when administered before elective surgery or percutaneous coronary interventions (39) , and recently, the American College of Cardiology/American Heart Association guidelines gave class IIa recommendation for the initiation of statin therapy before vascular surgery and class IIb recommendation for the initiation of statin therapy in patients with risk factors scheduled for intermediate risk surgery (21) . Animal studies have shown that statins protect against ischemia-reperfusion injury and when administered before ischemia (2, 5, 7, 31, 32, 46, 48, 49, 54, 55, 59, 62, 63, 68, 69) , or immediately upon reperfusion (4, 18, 62) , limit myocardial infarct size (IS). The activation of eNOS is essential for the IS-limiting effects of late ischemic preconditioning (8, 9, 53, 66) . Similarly, several investigators have shown that the activation of Akt and endothelial NOS (eNOS) is essential for the myocardial protective effect of statins, since nonspecific NOS inhibitors blunt the IS-limiting effect of statins (5, 63) and statins do not reduce IS in eNOS Ϫ/Ϫ mice (1, 4, 19, 31, 68, 71) . Inducible NOS (iNOS) activation is also essential for mediating the IS-limiting effects of statins. Scalia et al. (49) has shown that simvastatin does not limit IS in iNOS Ϫ/Ϫ mice. Our laboratory showed that 1400W, a specific iNOS inhibitor, abrogated the IS-limiting effects of atorvastatin in the rat without affecting eNOS (2) and, more recently, that atorvastatin failed to decrease IS in iNOS Ϫ/Ϫ mice (71) . The cardioprotection by preconditioning diminishes with age (17, 20, 30) , hypertension (17, 20) , diabetes (20) , and atherosclerosis (20) . The dependence on NOS activation may be a limitation, since it has been shown that both vascular (50, 52) and myocardial (44, 52) eNOS activity decreases with age, diabetes, and advanced atherosclerosis. It has been sug-gested that the dissociation of caveolin from caveolae occurs with aging and heart failure, leading to a decrease NOS activity (44) .
Thiazolidinediones, a class of drugs with peroxisome proliferator-activated receptor-␥ (PPAR␥) agonist activity, have been shown to reduce myocardial IS in the rat (29, 58, 60, 69, 73, 74) . In a study that compared the IS-limiting effects of atorvastatin and Pio in the rat, our group has found that a 3-day pretreatment with oral Pio at 10 mg⅐kg Ϫ1 ⅐day Ϫ1 limited IS and caused an insignificant increase in myocardial levels of phosphorylated (p)-Akt, without a detectable change in Ser1177 p-eNOS, and -iNOS levels (69) . In contrast, atorvastatin (10 mg⅐kg Ϫ1 ⅐day Ϫ1 ) caused a significant increase in myocardial p-Akt, Ser1177 p-eNOS and -iNOS levels (69) . Both atorvastatin and Pio upregulated cytosolic phospholipase A 2 (cPLA 2 ) and cyclooxygenase-2 (COX2) expression and activity, and the IS-limiting effects of both agents were abrogated with COX2 inhibitors (69 
Treatment
Protocol 1. Mice received a 3-day pretreatment with Pio (10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ) suspended in water or water alone, administered by oral gavage once daily. On the fourth day, mice underwent coronary artery ligation for 30 min followed by 4 h of reperfusion (IS protocol) (n ϭ 10 -12 in each group) or the mice were euthanized under anesthesia, and hearts were explanted without being subjected to ischemia, rinsed in cold PBS (pH 7.4) containing 0.16 mg/ml heparin to remove red blood cells and clots, frozen in liquid nitrogen, and stored at Ϫ80°C for further analyses (immunoblotting, 6-keto-PGF 1␣ levels, cPLA2 and COX2 activity, and real-time PCR) (n ϭ 4 in each group).
Protocol 2. Nineteen additional WT mice were treated as in protocol 1. However, 30 min before coronary artery occlusion, the mice received intraperitoneal saline or N G -nitro-L-arginine methyl ester (L-NAME), a nonselective NOS inhibitor (30 mg/kg), a dose found effective (61, 67) .
Infarct Size
On the fourth day, the mice were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (6 mg/kg), intubated, and ventilated (inspired oxygen fraction ϭ 30%). The rectal temperature was monitored and body temperature was maintained between 36.7°and 37.3°C throughout the experiment. The chest was opened and the left coronary artery was encircled with a suture and ligated for 30 min. Ischemia was verified by the regional dysfunction and discoloration of the ischemic zone. Isoflurane (1 to 2.0% titrated to effect) was added after the beginning of ischemia to maintain anesthesia. At 30 min of ischemia, the snare was released and myocardial reperfusion was verified by a change in the color of the myocardium. Subcutaneous 0.1 mg/kg buprenorphine was administered, the chest was closed, and the mice were recovered from anesthesia. Four hours after reperfusion, the mice were reanesthetized, the coronary artery was reoccluded, Evans blue dye (3%) was injected into the right ventricle, and the mice were euthanized under deep anesthesia (2, 7, 54, 69) .
The prespecified exclusion criteria were the lack of signs of ischemia during coronary artery ligation, the lack of signs of reperfusion after the release of the snare, a prolonged ventricular arrhythmia with hypotension, and an area at risk (AR) Յ 10% of the left ventricular weight.
Determination of AR and IS
Hearts were excised and the left ventricle was sliced transversely into six sections. Slices were incubated for 10 min at 37°C in 1% buffered (pH ϭ 7.4) 2,3,5-triphenyltetrazolium chloride, fixed in a 10% formaldehyde, and photographed to identify the AR (uncolored by the blue dye), the IS (unstained by 2,3,5-triphenyltetrazolium chloride), and the nonischemic zones (colored by blue dye). The AR and IS in each slice were determined by planimetry, converted into percentages of the whole for each slice, and multiplied by the weight of the slice, and the results were summed to obtain the weight of the myocardial AR and IS (2, 7, 54, 69) .
Immunoblotting
Myocardial samples from the left ventricular wall were homogenized in radioimmunoprecipitation assay lysis buffer (Santa Cruz Biotechnology) and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatant was collected and the total protein concentration was determined. The protein samples (50 g) in loading buffer were run in 4 -20% Tris ⅐ HCl Ready Gel at a 100 V for 2 h until the desired molecular weight bands were separated. After electrophoresis, the gel was equilibrated in transfer buffer (containing 25 mM Tris, 193 mM glycine, 0.1% SDS, and 10% methanol) and the proteins transferred to nitrocellulose membranes. The protein signals were quantified by an image-scanning densitometer, and the strength of each protein signal was normalized to the corresponding ␤-actin stain signal. Data are expressed as ratios between the protein and the corresponding ␤-actin signal density.
6-Keto-PGF 1␣ and PLA2 Activity
Myocardial samples of the anterior wall of the left ventricle were washed with a PBS solution (pH 7.4) to remove red blood cells and clots, homogenized in cold PBS (pH 7.4), and centrifuged. The supernatants were collected and stored on ice. Measurements of 6-keto-PGF 1␣, the stable metabolite of prostacyclin, and PLA2 activity were made using immunoassay kits.
COX Activity
Myocardial samples of the anterior wall of the left ventricle were rinsed with 0.05 M Tris buffer (pH 7.4) to remove any red blood cells and clots. The samples were homogenized in 5-10 ml of cold buffer (containing 0.1 M Tris ⅐ HCl, pH 7.8, with 1 mM EDTA) per gram tissue and centrifuged at 10,000 g for 15 min at 4°C, and the supernatant was collected and stored on ice. The COX activity assay kit measures the peroxidase activity of COX, assayed colorimetrically by monitoring the appearance of oxidized N,N,NЈ,NЈ-tetramethyl-pphenylenediamaine at 590 nm. Each myocardial sample was tested in triplicate: the first without an inhibitor; the second with DuP-697, a specific COX2 inhibitor; and the third with Sc560, a specific COX1 inhibitor. COX1 activity was calculated as the difference between the total COX activity in the sample without an inhibitor and the sample with Sc560, and COX2 activity as the difference between total COX activity in the sample without an inhibitor and the sample with DuP-697.
Real-Time PCR
PCR primers and probes. We used Applied Biosystems inventoried 20ϫ assay mixes of primers and TaqMan MGB probe (FAM dye labeled) for the target genes (see below) and predeveloped 18S rRNA (VIC dye-labeled probe) TaqMan assay reagent (P/N 4319413E) for endogenous control.
Assays-on-demand (P/N 4331182). The specification of probes used for real-time PCR were as follows: AP2, Mm00495574_m1; CD36, Mm00432403_m1; cPLA 2, Mm00447040_m1; COX2, Mm88242-ml; eNOS, Mm00435204_m1; and iNOS, Mm00440485_m1.
Relative quantitation of gene expression. Separate tubes (Singleplex) real-time PCR was performed with 40 ng cDNA for both target genes and endogenous control. The reagent that we used was the universal PCR master mix reagent kit (P/N 4304437). The cycling parameters for real-time PCR were UNG activation, 50°C for 2 min; AmpliTaq activation, 95°C for 10 min; denaturation, 95°C for 15 s, and annealing/extension, 60°C for 1 min (repeat 40 times) on ABI7000. Duplicate threshold cycle (C T) values were analyzed in Microsoft Excel using the comparative CT (⌬⌬CT) method as described by the manufacturer (Applied Biosystems). The amount of target (2 Ϫ⌬⌬CT ) was obtained by normalization to endogenous reference (18s) and relative to a calibrator (average of the control samples).
Materials
Pio was provided by Takeda Pharmaceuticals North America (Lincolnshire, IL). ELISA kits for 6-keto-PGF 1␣, cPLA2 activity, and COX activity were purchased from Cayman Chemicals (Ann Arbor, MI). Polyclonal anti-iNOS antibodies and L-NAME were purchased from Cayman Chemical; polyclonal anti-Ser1177 p-eNOS antibodies and anti-Ser633 p-eNOS antibodies from Cell Signaling (Beverly, MA); monoclonal anti-eNOS antibodies and monoclonal anti-COX2 antibodies from BD Bioscience (Franklin Lakes, NJ); monoclonal anti-cPLA 2 antibodies and anti-PGI2 synthase antibodies from Santa Cruz Biotechnology (Santa Cruz, CA), and monoclonal anti-␤-actin antibody from Sigma (St. Louis, MO).
Statistical Analysis
Data are presented as means Ϯ SE. The significance level ␣ is 0.05. Body weight, left ventricular weight, and the size of the AR and IS (as a percentage of the AR) in protocol 1 were compared using analysis of variance with Sidak corrections for multiple comparisons and in protocol 2 with Student's t-test. The data on enzyme expression and activity were compared between the Pio-treated and nontreated groups using t-test or Mann-Whitney rank sum test when appropriate. Values of P Ͻ 0.05 were considered statistically significant.
The authors had full access to the data and take responsibility for its integrity.
RESULTS

Infarct Size
Protocol 1. A total of 62 mice were included. None of the mice died or was excluded. Body weight, left ventricular weight, and AR size were comparable between the Pioϩ and PioϪ mice (Table 1) . Without Pio pretreatment, IS in the eNOS Ϫ/Ϫ (44.2 Ϯ 1.9%; P ϭ 0.35) and iNOS Ϫ/Ϫ mice (45.5 Ϯ 2.3%; P ϭ 0.11) tended to be bigger than in the WT mice (39.0 Ϯ 1.1%). Oral Pio decreased IS in all groups (Fig. 1) . However, the myocardial protective effect of Pio was significantly smaller in the eNOS Ϫ/Ϫ mice (32.0 Ϯ 1.6%) than in the WT (15.4 Ϯ 1.4%; P Ͻ 0.001) or iNOS Ϫ/Ϫ (18.0 Ϯ 1.2%; P Ͻ 0.001) mice.
Protocol 2. A total of 19 mice were included. Three mice (2 in the Pioϩ L-NAME and 1 in the L-NAME-alone group) died during surgery. Body weight, left ventricular weight, and AR size were comparable between the Pio ϩ L-NAME and L-NAME-alone groups (Table 2) . IS was significantly smaller in the Pio ϩ L-NAME group than in the L-NAME-alone group (Fig. 2) .
Immunoblotting
All immunoblotting analyses were done in hearts that were explanted on the fourth day of the experiment without being subjected to regional ischemia. Pio did not cause a detectable change in total eNOS levels in the WT and iNOS Ϫ/Ϫ mice. As expected, there was no expression of eNOS in the eNOS Ϫ/Ϫ mice (Fig. 3, A and B) . Pio caused a significant increase in myocardial Ser633 p-eNOS (Fig. 3, A and C) and Ser1177 p-eNOS (Fig. 3, A and D ) levels in the WT and iNOS Ϫ/Ϫ mice. iNOS was undetectable in all six groups (data not shown). There was no difference in neuronal NOS (nNOS) levels among the groups (Fig. 3A) .
Pio increased cPLA 2 (Fig. 4, A and B) , COX2 (Fig. 4 , A and C), and PGI 2 synthase (Fig. 4, A and D) levels in the WT, as well as in the eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice.
Real-Time PCR
We used AP2 and CD36 as markers of PPAR␥ activation. Pio increased AP2 mRNA levels in the WT and iNOS Ϫ/Ϫ mice and, to a lesser extent, in the eNOS Ϫ/Ϫ mice (Fig. 5A) . Pio increased CD36 mRNA levels in the WT, as well as in the eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ , mice (Fig. 5B) . Pio increased eNOS mRNA levels in the WT and iNOS Ϫ/Ϫ mice (Fig. 5C ) and caused a small, yet statistically significant, decrease in iNOS mRNA levels in the WT and eNOS Ϫ/Ϫ mice (Fig. 5D ). Both , and iNOS Ϫ/Ϫ mice.
Myocardial 6-Keto-PGF 1␣ Levels and cPLA 2 and COX Activity
Pio increased myocardial 6-keto-PGF 1␣ levels in the WT, eNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice (Fig. 6A) . cPLA 2 activity was increased by Pio in the WT and iNOS Ϫ/Ϫ mice and, to a lesser extent, in the eNOS Ϫ/Ϫ mice (Fig. 6B ). Pio caused a small, yet significant, increase in COX1 activity (Fig. 6C) . COX2 activity was increased by Pio, especially in the WT mice, and to a lesser extent in the eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice (Fig. 6D ).
DISCUSSION
Our main findings are that in contrast to the IS-limiting effect of statins which is eNOS and iNOS dependent (71), Pio limits IS in the WT, as well as in the iNOS Ϫ/Ϫ , mice. In the eNOS Ϫ/Ϫ mice, Pio significantly reduced IS; however, the effect was smaller than in the WT and iNOS Ϫ/Ϫ mice. This may suggest that the protective effect of Pio is partially dependent on eNOS. However, blocking all three NOSs (eNOS, iNOS and nNOS) with L-NAME did not attenuate the IS-limiting effects of Pio. Thus an alternative explanation can be the genetic differences among the various mice strains. Pio increased the expression and activity of cPLA 2 and COX2 and myocardial 6-keto-PGF 1␣ levels in all three strains of mice.
Role of eNOS
eNOS is essential for mediating late ischemic preconditioning (8 ) limits IS without causing a detectable change in myocardial Ser1177 p-eNOS levels, although there was a small increase in calcium-dependent NOS activity (69), which could have been attributed to Ser633 phosphorylation by protein kinase A. On the other hand, atorvastatin had a similar magnitude of myocardial protective effect in the rat but induced an increase in Ser1177 p-eNOS levels, although the total eNOS levels did not change (7, 46, 69) . In contrast, in the mouse, the same regiment of atorvastatin pretreatment increases myocardial levels of both total eNOS and Ser1177 p-eNOS (71), suggesting that there are some differences between mice and rats in response to drugs. However, the general response is the activation of eNOS. In contrast to the effects of atorvastatin in mice, Pio caused an increase in eNOS mRNA without a detectable change in total eNOS protein levels. In the mouse, in contrast to the rat, Pio caused a small, yet significant, increase in eNOS phosphorylation at both Ser633 and Ser1177, suggesting the activation by protein kinase A (and/or other kinases) (26) . Other studies have suggested that PPAR␥ agonists increase NO production by eNOS without affecting the total eNOS expression (10, 28, 47) . Hwang et al. (28) reported that ciglitazone increases the bioavailability of NO by an increased expression of Cu/Zn-superoxide dismutase and a suppression of NADPH oxidase. On the other hand, Cho et al. (12) reported that a prolonged treatment with troglitazone increased calcium-dependent NOS activity in bovine aortic endothelial cells by augmenting eNOS phosphorylation at Ser1179 without a detectable change in the total eNOS levels. Huang et al. (27) showed that Pio increases eNOS phosphorylation at Ser1177 in diabetic mice. Although Pio induced a small increase in eNOS phosphorylation in the WT as well as the iNOS Ϫ/Ϫ mice, eNOS was not essential for mediating cPLA 2 , COX2, and PGI 2 synthase upregulation and activation. One may conclude that the myocardial protective effect of Pio is partially mediated by eNOS, since IS was significantly larger in the Pio-treated eNOS Ϫ/Ϫ than in the Pio-treated WT and iNOS Ϫ/Ϫ mice. Indeed, the nonspecific inhibition of NOS with N G -monomethyl-L-arginine blunted the effect of Pio on insulin resistance without affecting eNOS and iNOS protein levels in rat skeletal muscles (37) . It was reported that rosiglitazone Values are means Ϯ SE; n, number of mice. L-NAME, N G -nitro-L-arginine methyl ester. failed to protect eNOS Ϫ/Ϫ mice from stunning post ischemiareperfusion injury (22) , since it did so in the WT mice, suggesting that in contrast to rosiglitazone, Pio may have an additional eNOS-independent mechanism of protection. It is plausible that the explanation for the smaller effect of Pio on IS in the eNOS Ϫ/Ϫ may be related to the genetic background of the strain and not to a partial dependence on eNOS, since L-NAME did not affect the IS-limiting effect of Pio (protocol 2). The dose of L-NAME used in the study (30 mg/kg) is sufficient to block all NOS, as Wolfrum et al. (61) reported that at 15 mg/kg, L-NAME blocked the IS-limiting effects of fasudil.
Role of iNOS
iNOS is essential for mediating late ischemic preconditioning (8) . As mentioned in the introduction, iNOS is essential for the IS-limiting effects of statins (2, 49, 71) since iNOS is needed for the activation of COX2 (2, 6, 34, 71) and cPLA 2 (65) by S-nitrosylation. Several investigators have suggested that ciglitazone (14) , rosiglitazone (15, 16) , and Pio (15, 36) reduce iNOS expression and activity in various experimental models. The present study shows that in contrast to statins, Pio did not augment iNOS expression; moreover, Pio limited IS in iNOS Ϫ/Ϫ mice as it did in the WT mice, whereas statins do not (49, 71) , emphasizing the fact that the activating pathways of myocardial protection by statins and Pio are different. It has been suggested that the other forms of NOS may compensate for the knockout of one of the isoforms. For example, the upregulation of eNOS in iNOS Ϫ/Ϫ mice can mediate preconditioning by the adenosine A 1 receptor agonist, 2-chloro-N 6 -cyclopentyladenosine (3). However, the protective effect of 2-chloro-N 6 -cyclopentyladenosine was blocked by L-NAME. Wang et al. (57) reported that nNOS mediates late preconditioning in rabbits. In the present experiment, there were no differences in nNOS levels between the WT, eNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice. Pio did not affect nNOS expression in all three types of mice. Moreover, Pio reduced IS in mice pretreated with L-NAME, a nonselective NOS inhibitor, supporting our conclusion that the protective effect of Pio is NOS independent and that cross coverage among the NOS isoforms cannot explain the protective effect in the knockout mice.
Role of cPLA 2 and COX2
Our laboratory has shown that a 3-day pretreatment with atorvastatin upregulates cPLA 2 and COX2 expression and activity in rats (2, 7, 69) and mice (71) . COX2 inhibition, either with an oral COX2 inhibitor during the 3-day pretreatment with atorvastatin (7) or acutely, just before coronary artery occlusion (2), abrogates the IS-limiting effect of atorvastatin in the rat. A 3-day pretreatment with Pio (10 mg⅐kg Ϫ1 ⅐day Ϫ1 ) also increases cPLA 2 and COX2 expression and activity in the rat (69) . The IS-limiting effect of Pio is abrogated with COX2 inhibition, but not with COX1 inhibition (69) .
A previous study suggested that PLA 2 is involved in ischemic preconditioning (51) . Atorvastatin increases cPLA 2 expression in the WT, as well as eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice, yet cPLA 2 activity increases by atorvastatin only in the WT mice, suggesting that eNOS and iNOS are essential for cPLA 2 activation (70). Indeed, it has recently been shown that iNOS activates cPLA 2 by S-nitrosylation (65) . In contrast, in the present study, Pio increased cPLA 2 expression to a similar extent in the WT, eNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice (Fig. 4) ; however, cPLA 2 activity was augmented to a larger extent by Pio in the WT than in both the eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice (Fig. 6 ). Thus cPLA 2 activation by Pio may be partially eNOS and iNOS independent.
It has been suggested that COX2 is activated to produce PGH 2 by iNOS-induced S-nitrosylation (2, 6, 34, 71) . Pio upregulated COX2 expression in the WT, as well as in the eNOS Ϫ/Ϫ and iNOS
, mice (Fig. 4) . Although the augmentation of COX2 activity by Pio was smaller in the eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice than in the WT mice, myocardial 6-keto-PGF 1␣ levels were comparable among the Pio-treated WT, eNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice (Fig. 6 ). The discrepancy between myocardial 6-keto-PGF 1␣ levels and COX2 activity is unclear. It may be related to PGI 2 synthase activity or a better coupling between COX2 and PGI 2 synthase. The fact that COX2 is activated by Pio without a detectable increase in iNOS in the WT and eNOS Ϫ/Ϫ mice and in the iNOS Ϫ/Ϫ mice suggests a different, yet undefined, posttranslation modification of COX2 in addition to the described S-nitrosylation. It might be that in the WT mice, COX2 is activated by both S-nitrosylation and NOS-independent pathways. This is a possible explanation to the greater increase in COX2 activity by Pio in the WT mice.
Pio is a thiazolidinedione with PPAR␥ agonist activity. AP2 and CD36 are PPAR␥-dependent genes encoding proteins involved in lipid transport and storage (72) . We measured the expression of these genes in response to Pio as a measure of PPAR␥ activation. Indeed, Pio activated PPAR␥ in the WT, eNOS Ϫ/Ϫ , and iNOS Ϫ/Ϫ mice. The upregulation of CD36, and especially AP2 by Pio, was lower in the eNOS Ϫ/Ϫ than in the WT and iNOS Ϫ/Ϫ mice (Fig. 5 ). This correlates with the magnitude of IS limitation by Pio in the various mice strains (Fig. 1) . However, it has not been previously reported that the activation of PPAR␥ by Pio is dependent on eNOS. In contrast, it has been shown that eNOS Ϫ/Ϫ mice have insulin resistance and an impaired exocrine pancreatic secretion function. Pio improves both the exocrine secretion function and insulin resistance in eNOS Ϫ/Ϫ mice (45) . Using human umbilical vein endothelial cells, our laboratory has shown that Pio increases the production of PGD 2 and 15-deoxy-⌬-12,14-PGJ 2 , which is formed by the nonenzymatic conversion of PGD 2 (72). The effect of Pio is attenuated by Sc58125, a selective COX2 inhibitor and small-interfering RNA to PGD 2 synthase, but not by GW9662, a PPAR␥ antagonist, suggesting that the upregulation of PGD 2 synthase is independent of PPAR␥ activation (72) . We are currently investigating whether Pio limits IS and augments myocardial cPLA 2 and COX2 in a cardiac-targeted PPAR␥ Ϫ/Ϫ mice.
Limitations
In the present study, we assessed IS after 30 min of ischemia and 4 h of reperfusion. It might be that the protective effect could be different if longer reperfusion periods were used. It should be further investigated whether the IS-limiting effects of pretreatment with Pio last with longer reperfusion periods (days and/or weeks) and whether the continuation of treatment is needed to sustain the effect after the induction of myocardial infarction.
As in our previous studies, we used ketamine and xylazine to induce anesthesia and isoflurane to maintain it. We added buprenorphine for analgesia before chest closure. One study suggested that ketamine preconditions isolated human right atrial myocardial cells by opening ATP-sensitive channel and stimulation of ␣-and ␤-adrenergic receptors (25) . However, others suggested that myocardial norepinephrine levels were not increased by ischemic preconditioning in rabbits anesthetized with xylazine-ketamine, whereas they were increased in rabbits anesthetized with pentobarbital sodium (40) and that ketamine deactivates myocardial ATPsensitive potassium channels (35) . Most investigators report that ketamine may attenuate preconditioning (24, 33, (41) (42) (43) . Isoflurane (13, 56) and opioid agonists (23) have been shown to protect against ischemia-reperfusion injury and reduce IS. Although we added all agents after the beginning of ischemia, recent studies have suggested that morphine has a postconditioning effect (11) . We observed a significant effect of Pio on IS using the above-mentioned anesthetic regimen. However, others have reported that Pio limits IS in animals anesthetized with pentobarbital sodium (29, 64) . Moreover, we have recently shown, using an identical model with the same regimen of anesthesia, that atorvastatin failed to limit IS in eNOS Ϫ/Ϫ and iNOS Ϫ/Ϫ mice (71). Thus we do not think that the anesthetic regimen had a significant effect on our results.
It should be remembered that Pio might exacerbate heart failure (38); however, ␤-blockers, the other class of drugs approved for perioperative treatment for the reduction of cardiovascular events in high-risk patients (21) , may also induce/ exacerbate heart failure. In conclusion, the myocardial protective effect of Pio is iNOS independent and may be only partially dependent on eNOS. It seems that the magnitude of myocardial protection correlates with the magnitude of activation of PPAR␥, at least as assessed by AP2 levels. Pio increases myocardial 6-keto-PGF 1␣ levels by upregulating and activating cPLA 2 , COX2, and PGI 2 synthase by an eNOS-and iNOS-independent mechanism. The partial independence of eNOS may have potential clinical implications since it has been shown that eNOS activity decreases with age, diabetes, and advanced atherosclerosis (50) . Thus Pio may be particularly beneficial in these high-risk subsets. Further studies are needed for comparing the effects of statins and Pio on myocardial protection in aged animals, as well as in animals with diabetes and advanced atherosclerosis.
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